期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

尿激酶型纤溶酶原激活剂mRNA在胃癌组织中的表达及其意义 被引量：1

Study on Expression of Urokinase-Type Plasminogen Activator mRNA in Gastric Cancer
暂未订购
导出
摘要 目的　研究尿激酶型纤溶酶原激活剂 (uPA)mRNA在胃癌组织中的表达及其意义。方法　应用荧光定量RT PCR方法 ,分别检测 4 8例胃癌及其癌旁组织中uPAmRNA的表达 ,并结合其临床病理特征进行分析。结果　 4 8例胃癌组织及癌旁组织中 ,uPAmRNA表达阳性率分别为 83.3%和 2 5 .0 %。胃癌伴有淋巴结转移和无淋巴结转移者中 ,uPAmRNA表达阳性率分别为 93.8%和 6 2 .5 % ,且uPAmRNA表达与胃癌浸润程度呈正相关。结论　uPAmRNA表达可作为判断胃癌恶性程度及预后的指标之一。 Objective To investigate the expression of urokinase-type plasminogen activator (uPA) mRNA in gastric cancer tissues and cancer-adjacent tissues and the relationship between its expression and biologic behavior of tumor. Methods Fourty-eight cases with gastric cancer were detected for the expression of uPA mRNA by fluorogenic probe quantitative reverse transcription polymerase chain reaction (RT-PCR). Results The positive expression rate of uPA mRNA was 83.3%, 25.0%, 93.8% and 62.5% in gastric cancer tissues,cancer-adjacent tissues, gastric cancer tissues with lymph node metastasis and with non-lymph node metastasis respectively. Expression of uPA mRNA was positively related with the invasion depth of gastric cancer.Conclusion Expression of uPA mRNA is significantly increased in gastric cancer and it can be used as an indicator to judge the metastasis and prognosis of tumor.
作者 熊俊 郑启昌 宋自芳
机构地区 华中科技大学同济医学院附属协和医院普外科
出处 《中国普外基础与临床杂志》 CAS 2004年第2期116-118,共3页 Chinese Journal of Bases and Clinics In General Surgery
关键词 尿激酶型纤溶酶原激活剂 UPA 胃癌组织 基因表达 MRNA 肿瘤细胞 Gastric cancer Urokinase-type plasminogen activator
分类号 R735.2 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1[1]Astedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture [J]. Nature, 1976; 261(5561):595
  • 2[2]Chambers SK, Gertz RE Jr, Ivins CM, et al. The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer [J]. Cancer, 1995; 75(7):1627
  • 3[3]Konecny G, Untch M, Arboleda J, et al. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer [J]. Clin Cancer Res, 2001; 7(8):2448
  • 4[4]Ito H, Yonemura Y, Fujita H, et al. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer [J]. Virchows Arch, 1996; 427(5):487
  • 5[5]Heiss MM, Babic R, Allgayer H, et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system [J]. J Clin Oncol, 1995; 13(8):2084
  • 6[6]Hsu DW, Efird JT, Hedley-Whyte ET. Prognostic role of urokinase-type plasminogen activator in human gliomas [J]. Am J Pathol, 1995; 147(1):114
  • 7[7]Duggan C, Maguire T, McDermott E, et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer [J]. Int J Cancer, 1995; 61(5):597
  • 8[8]Schneider J, Pollan M, Tejerina A, et al. Accumulation of uPA-PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer [J]. Br J Cancer, 2003; 88(1):96
  • 9[9]Spyratos F, Bouchet C, Tozlu S, et al. Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer [J]. Anticancer Res, 2002; 22(5):2997
  • 10[10]Casella R, Shariat SF, Monoski MA, et al. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma [J]. Cancer, 2002; 95(12):2494

同被引文献12

  • 1Harbeck N, Kates RE, Gauger K, et al. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer [J]. Thromb Haemost, 2004; 91(3):450.
  • 2Thomssen C, Janicke F, Harbeck N. Clinical relevance of prognostic factors in axillary node-negative breast cancer [J]. Onkologie, 2003; 26(5):438.
  • 3Hsu DW, Efird JT, Hedley-Whyte ET. Prognostic role of urokinase-type plasminogen activator in human gliomas [J]. Am J Pathol, 1995; 147(1):114.
  • 4Zemzoum I, Kates RE, Ross JS, et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer [J]. J Clin Oncol, 2003; 21(6):1022.
  • 5Guo Y, Pakneshan P, Gladu J, et al. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion [J]. J Biol Chem, 2002; 277(44):41571.
  • 6Harbeck N, Schmitt M, Kates RE, et al. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts [J]. Clin Breast Cancer, 2002; 3(3):196.
  • 7Hemsen A, Riethdorf L, Brunner N, et al. Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells [J]. Int J Cancer, 2003; 107(6):903.
  • 8Qin W, Zhu W, Wagner-Mann C, et al. Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease [J]. Ann Surg Oncol, 2003; 10(8):948.
  • 9Qin W, Zhu W, Wagner-Mann C, et al. Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer [J]. Cancer J, 2003; 9(4):293.
  • 10Manders P, Tjan-Heijnen VC, Span PN, et al. Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer [J]. Cancer Res, 2004; 64(2):659.

引证文献1

中国普外基础与临床杂志
2004年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部